Fidelity Investments
FDMT icon

Fidelity Investments’s 4D Molecular Therapeutics FDMT Stock Holding History

Fidelity Investments’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.46M Buy
311,944
+183,628
+143% +$2.39M ﹤0.01% 2490
2026
Q2 		$1.71M Buy
128,316
+58,219
+83% +$567K ﹤0.01% 2810
2026
Q1 		$653K Buy
70,097
+4,448
+7% +$38.7K ﹤0.01% 3017
2025
Q4 		$492K Buy
65,649
+79
+0.1% +$801 ﹤0.01% 3090
2025
Q3 		$570K Buy
65,570
+3,504
+6% +$20.9K ﹤0.01% 2985
2025
Q2 		$230K Buy
62,066
+54,200
+689% +$191K ﹤0.01% 3257
2025
Q1 		$25.4K Buy
7,866
+5,824
+285% +$27.4K ﹤0.01% 4134
2024
Q4 		$11.4K Sell
2,042
-2,058
-50% -$16.2K ﹤0.01% 4424
2024
Q3 		$44.3K Sell
4,100
-1,012,123
-100% -$16.8M ﹤0.01% 3830
2024
Q2 		$21.3M Buy
1,016,223
+47,341
+5% +$1.19M ﹤0.01% 1622
2024
Q1 		$30.9M Buy
968,882
+965,245
+26,540% +$24.6M ﹤0.01% 1508
2023
Q4 		$73.7K Buy
3,637
+881
+32% +$11.6K ﹤0.01% 3345
2023
Q3 		$35.1K Sell
2,756
-76
-3% -$1.27K ﹤0.01% 3523
2023
Q2 		$51.2K Buy
2,832
+138
+5% +$2.54K ﹤0.01% 3418
2023
Q1 		$46.3K Sell
2,694
-24,208
-90% -$471K ﹤0.01% 3483
2022
Q4 		$597K Sell
26,902
-261,302
-91% -$4.04M ﹤0.01% 2665
2022
Q3 		$2.32M Sell
288,204
-412,248
-59% -$3.73M ﹤0.01% 2394
2022
Q2 		$4.89M Sell
700,452
-390,766
-36% -$3.8M ﹤0.01% 2244
2022
Q1 		$16.5M Sell
1,091,218
-48,957
-4% -$769K ﹤0.01% 1873
2021
Q4 		$25M Buy
1,140,175
+118,202
+12% +$2.9M ﹤0.01% 1720
2021
Q3 		$27.6M Sell
1,021,973
-15,753
-2% -$449K ﹤0.01% 1681
2021
Q2 		$25M Sell
1,037,726
-249,845
-19% -$7.65M ﹤0.01% 1744
2021
Q1 		$55.9M Sell
1,287,571
-306,784
-19% -$13.6M ﹤0.01% 1348
2020
Q4 		$66.1M Buy
+1,594,355
New +$65.8M 0.01% 1210

Other funds holding FDMT

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Fidelity Investments's FDMT Position: Q3 2026 in Review

Fidelity Investments increased its 4D Molecular Therapeutics (FDMT) stake by 143% in Q3 2026, buying an estimated $2.39M and bringing the position to 311,944 shares worth $4.46M. The position accounts for ﹤0.01% of the portfolio, ranked #2490.

Fidelity Investments first reported a position in FDMT in Q4 2020 and has held it in 24 quarters since. The position peaked at $66.1M in Q4 2020. 110 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.

  • Fidelity Investments held 311,944 shares of 4D Molecular Therapeutics worth $4.46M as of Q3 2026.
  • Fidelity Investments bought 183,628 4D Molecular Therapeutics shares in Q3 2026, an estimated $2.39M.
  • 4D Molecular Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q3 2026, its #2490 holding.
  • Fidelity Investments first reported a position in 4D Molecular Therapeutics in Q4 2020 and has held it in 24 quarters since.
  • Fidelity Investments's 4D Molecular Therapeutics position peaked at $66.1M in Q4 2020.
  • 110 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.

Based on Fidelity Investments's 13F filing for Q3 2026, filed 10 Nov 2026.